Autres langues Fulcrum Therapeutics, Inc.

Actions

FULC

US3596161097

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 29/04/2024			Varia. 5j.	Varia. 1 janv.
7,08 ^USD	-0,84%		-2,34%	+4,89%

18/03	Fulcrum Therapeutics nomme Patrick Horn au poste de médecin-chef	MT
18/03	Fulcrum Therapeutics, Inc. annonce des changements au niveau de la direction	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium	28/03
Fulcrum Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	25/03
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	22/03
Fulcrum Therapeutics Appoints Patrick Horn as Chief Medical Officer	18/03
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer	18/03
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer	18/03
Fulcrum Therapeutics, Inc. Announces Executive Changes	18/03
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) added to S&P Pharmaceuticals Select Industry Index	18/03
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	08/03
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	08/03
Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference	05/03
GSK : la Dr Jeannie Lee entre au conseil d'administration	29/02
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023	28/02
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023	27/02
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/02
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023	27/02
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET	20/02
Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	06/02
Fulcrum Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	08/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Fulcrum Therapeutics, Inc.

Actions

FULC

US3596161097

Autres langues

Filtres